Pacira Biosciences, Inc. (PCRX)
| Market Cap | 2.89B |
| Revenue (ttm) | 580.50M |
| Net Income (ttm) | 38.44M |
| Shares Out | 45.44M |
| EPS (ttm) | 0.84 |
| PE Ratio | 75.79 |
| Forward PE | 19.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,717 |
| Open | 63.97 |
| Previous Close | 63.04 |
| Day's Range | 61.96 - 64.54 |
| 52-Week Range | 45.05 - 82.16 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 82.07 (+29.1%) |
| Earnings Date | May 4, 2022 |
About PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsula...
Financial Performance
In 2021, PCRX's revenue was $541.53 million, an increase of 26.04% compared to the previous year's $429.65 million. Earnings were $41.98 million, a decrease of -71.15%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is 82.07, which is an increase of 29.06% from the latest price.
News
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.
Pacira (PCRX) Q1 Earnings Miss Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira BioSciences Reports First Quarter 2022 Financial Results
-- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call today at 8:30 a.m. ...
Why Pacira (PCRX) Could Beat Earnings Estimates Again
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Small-Cap Medical Stocks With Big Momentum
Now is a good time to take a closer look at these stocks.
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Pacira (PCRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual Health...
Pacira (PCRX) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Confere...
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates
Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patie...
Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira to Report 2021 Financial Results on Thursday February 24, 2022
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before the...
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022
-- EXPAREL average daily sales for January 2022 were 104% of January 2021 -- -- EXPAREL average daily sales for January 2022 were 104% of January 2021 --
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Reasons to Bet On These 5 Buy Ranked Stocks
PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow --
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021
-- EXPAREL average daily sales for November 2021 - 122% of November 2020 –
Pacira (PCRX) Down 4.5% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
TAMPA, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual H...
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pa...
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --